Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:11 AM ET 8-K
Financial Results Theriva Biologics, Inc. TOVX

Theriva Biologics Financial Results

Theriva Biologics reported third quarter 2026 financial results, highlighting a cash position of $8.5 million and a runway into Q1 2027. The company also noted the completion of the sale of its SYN-004 portfolio to Biossil Labs for $350,000 upfront and up to $91 million in milestones.

“We are pleased with the clinical progress achieved this quarter. Patient enrollment and dosing in the VIRAGE2 trial is progressing well, and we anticipate completing enrollment by the end of the fourth quarter of this year.”

Steven A. Shallcross, Chief Executive Officer of Theriva Biologics

“The recently signed asset sale agreement for SYN-004 (ribaxamase) and the related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. demonstrates our commitment to deriving value from our legacy microbiome programs while continuing to focus on the development of our lead program VCN-01.”

Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
8:10 AM ET 8-K
M&A Deal Silence Therapeutics plc SLN

Silence Therapeutics M&A Deal with Merck KGaA

Silence Therapeutics announced it has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The transaction is expected to close in the first quarter of 2027, subject to customary closing conditions and shareholder approval. While the filing also contains Q3 2026 financial results, the pending acquisition is the primary material event for investors.

Counterparty
Merck KGaA
8:10 AM ET 8-K
M&A Deal Inflection Point Acquisition Corp. VII IPXG

Inflection Point Acquisition Corp. VII M&A Deal with Elroy Air, Inc.

Inflection Point Acquisition Corp. VII entered into a second amendment to its business combination agreement with Elroy Air, Inc. The amendment simplifies the stock exchange process by eliminating the requirement for letters of transmittal and updates the closing conditions regarding seller lock-up agreements for certain equity holders and employees.

Counterparty
Elroy Air, Inc.
8:10 AM ET 8-K
Financial Results enCore Energy Corp. EU

enCore Energy Financial Results

enCore Energy reported Q3 2026 revenue of $16.7 million, an 88% increase year-over-year driven by higher uranium delivery volumes and stronger realized prices. The company reported a net loss of $33.9 million for the quarter as it focused on wellfield development at Alta Mesa and Upper Spring Creek while implementing cost-reduction measures.

Term
Q3 2026

“2026 has been a challenging year for enCore, and we have responded by reducing costs and focusing our capital where it matters most. We optimized operations to align spending with permitting timelines, while continuing to build the wellfields and infrastructure that underpin our next phase of extraction.”

Rich Little, Chief Executive Officer
8:09 AM ET 8-K
Shareholder Meeting Health In Tech, Inc. HIT

Health In Tech Shareholder Meeting

Health In Tech held its 2026 Annual Meeting of Stockholders where shareholders elected five directors and approved an amendment to increase authorized capital stock from 220 million to 720 million shares. Additionally, stockholders approved the potential issuance of Class A Common Stock under a Standby Equity Purchase Agreement and an amendment to the 2024 Equity Incentive Plan to increase authorized shares to 30.7 million.

8:09 AM ET 10-Q
Financial Results Aktis Oncology, Inc. AKTS

Aktis Oncology Q3 2026 Results: Net Loss of $29.9M, Loss Widens

Aktis Oncology reported a net loss of $72.4 million for the nine months ended September 30, 2026, compared to $48.6 million in the prior year, driven by increased R&D and G&A expenses. The company significantly strengthened its balance sheet during the period through an initial public offering and the conversion of preferred stock, ending the quarter with $492.9 million in cash and marketable securities.

Key figure
Net loss $29.9M
8:09 AM ET 8-K
Leadership Change Hubspot Inc HUBS

Hubspot Leadership Change

HubSpot announced that Yamini Rangan has stepped down as CEO and board member, with co-founder Brian Halligan returning as President and CEO effective November 12, 2026. Additionally, CFO Kate Bueker will retire in February 2027 and be succeeded by Karen Burgess, formerly of Adobe. The company framed the leadership transition as a 'refounding' to focus on AI-driven customer relationship tools.

8:08 AM ET 8-K
Financial Results Avalyn Pharma Inc. AVLN

Avalyn Pharma Financial Results

Avalyn Pharma reported financial results for the third quarter of 2026, ending the period with $386.6 million in cash and a runway projected into 2029. The company highlighted clinical progress, including the initiation of a Phase 1 study for its AP03 combination therapy and upcoming Phase 2 data readouts for AP01 and AP02 expected in 2027.

Term
Q3 2026

“As we approach year end, I’m proud of the progress we’ve made across our portfolio and the strong foundation we’ve built for what we expect to be a transformational 2027, with data anticipated across all three of our programs.”

Lyn Baranowski, Chief Executive Officer of Avalyn

“We remain confident in the potential of inhaled therapies to transform the standard of care for pulmonary fibrosis by delivering effective, well-tolerated treatments both as monotherapies and in combination.”

Lyn Baranowski, Chief Executive Officer of Avalyn
8:08 AM ET 8-K
Financial Results MeiraGTx Holdings plc MGTX

MeiraGTx Holdings Financial Results

MeiraGTx reported third quarter 2026 financial results and provided a regulatory update for its lead candidate bota-vec, with an MAA submission to the EMA expected in December 2026 and a BLA submission to the FDA in Q1 2027. The company is preparing for a potential commercial launch of bota-vec for XLRP in late 2027 while advancing its Phase 2 AQUAx2 study for radiation-induced xerostomia.

“We are pleased to report that we have now completed much of the work towards submission of full global regulatory filings with the EMA and FDA for bota-vec for the treatment of XLRP. The MAA dossier is complete and awaiting submission and the BLA is expected to follow early next year.”

Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx

“We are actively preparing for our pivotal Phase 2 AQUAx2 12-month data readout for the treatment of radiation-induced xerostomia in mid-2027. As we progress these two lead programs through filing for potential approval and commercialization, we are also advancing several programs towards IND.”

Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx
8:08 AM ET 8-K
Leadership Change Profound Medical Corp. PROF

Profound Medical Leadership Change

Profound Medical Corp. announced a leadership transition where Richard R. Fabian will succeed Arun Menawat as President and CEO effective January 15, 2027, with Dr. Menawat becoming Executive Chairman. Additionally, Jason Mills was appointed to the Board of Directors following the resignation of Cynthia Lavoie.

8:07 AM ET 10-Q
Financial Results Liqtech International Inc LIQT

Liqtech International Q3 2026 Results: Net Loss of $1.84M, Loss Widens

LiqTech International reported revenue of $12.9 million for the nine months ended September 30, 2026, a slight decrease from $13.4 million in the prior year period. The company significantly strengthened its balance sheet, increasing cash to $13.9 million and total stockholders' equity to $24.3 million, primarily through the issuance of common stock and the settlement of notes payable.

Key figure
Net loss $1.84M
8:06 AM ET 10-Q
Financial Results Creatd, Inc. CRTD

Creatd Q3 2026 Results: Net Loss of $2.77M, Loss Widens

Creatd, Inc. reported a significant increase in net loss for the nine months ended September 30, 2026, reaching $20.2 million compared to $5.1 million in the prior year, primarily driven by a surge in stock-based compensation and general administrative expenses. Net revenue declined by approximately 27% year-over-year to $603,722, while the company's total stockholders' equity decreased to $7.97 million.

Key figure
Net loss $2.77M
8:06 AM ET 8-K
Capital Raise Prime Medicine, Inc. PRME

Prime Medicine Capital Raise of $144M

Prime Medicine, Inc. entered into an underwriting agreement for a public offering of 35,714,286 shares of common stock at $3.50 per share. The company also granted underwriters a 30-day option to purchase up to an additional 5,357,142 shares, bringing the total potential gross proceeds to approximately $143.75 million. Proceeds will be used to advance the company's Wilson disease and alpha-1 antitrypsin deficiency programs and for general corporate purposes.

Value
$144M
Counterparty
Jefferies LLC
8:05 AM ET 8-K
Deal Termination Western Union CO WU

Western Union Deal Termination with International Money Express, Inc.

Western Union terminated its definitive merger agreement to acquire International Money Express (Intermex) after failing to reach acceptable terms with California's Department of Financial Protection and Innovation (DFPI). The regulator imposed conditions that would have required material changes to Western Union's business model and agent relationships, which the company deemed not in the best interests of shareholders. No termination fee is payable by either party, though Intermex has reportedly threatened legal action regarding the termination.

Counterparty
International Money Express, Inc.
8:05 AM ET 8-K
Financial Results Lucid Diagnostics Inc. LUCD

Lucid Diagnostics Financial Results

Lucid Diagnostics reported third quarter 2026 financial results, highlighting the commencement of Medicare reimbursement for its EsoGuard Esophageal DNA Test at a rate of $1,938.01 per test. The company performed 2,871 tests during the quarter and reported record monthly test volume in October following the Medicare coverage milestone.

“Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test. This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth.”

Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer

“Our pursuit of EsoGuard’s enormous clinical and commercial opportunity is now substantially less constrained by external factors. Lucid’s near-term growth now depends almost entirely on our team’s commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth. What has been a marathon is now a sprint.”

Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer
8:05 AM ET 8-K
Financial Results Aktis Oncology, Inc. AKTS

Aktis Oncology Financial Results

Aktis Oncology reported financial results for the third quarter of 2026, highlighting the initiation of its third Phase 1b clinical trial (BActinium-2) for AKY-2519. The company also operationalized its in-house GMP manufacturing facility in Boston and remains on track to present preliminary clinical data for its lead programs in 2027.

Term
Q3 2026

“Aktis is on a trajectory to redefine radiopharmaceuticals as a major pillar of cancer treatment by expanding the modality to more targets, broader indications, and larger patient populations. In the third quarter, we continued to make tremendous progress operationalizing this vision.”

Matthew Roden, Ph.D., President and Chief Executive Officer

“With the initiation of the BActinium-2 trial of AKY-2519, we now have three clinical trials underway in the U.S. across two novel targets, Nectin-4 and B7-H3, which are both implicated in a range of solid tumor types. We also opened the first backfill cohorts in our ongoing NECTINIUM-2 and BActinium-1 trials to further characterize safety and preliminary antitumor activity at the selected doses, while dose escalation continues in both studies.”

Matthew Roden, Ph.D., President and Chief Executive Officer
8:05 AM ET 10-Q
Financial Results Kyverna Therapeutics, Inc. KYTX

Kyverna Therapeutics Q3 2026 Results: Net Loss of $41.9M, Loss Widens

Kyverna Therapeutics reported a net loss of $119.99 million for the nine months ended September 30, 2026, compared to $123.50 million in the prior year period. The company's cash and marketable securities position decreased to $170.57 million as of September 30, 2026, down from $279.25 million at the end of 2025, primarily due to ongoing research and development expenses.

Key figure
Net loss $41.9M
8:04 AM ET Form 4
Insider Selling Scotts Miracle-Gro Co SMG

Scotts Miracle-Gro Insider David C. Evans Sells $176K of Stock

David C. Evans sold 2,655 shares of Scotts Miracle-Gro Co at $66.42 a share, worth $176K in total on Nov 9, 2026. Shares held after the trade: 25,405 (-9.5%).

Value
$176K
Shares
2,655
Price
$66.42
Holding change
-9.5%
Trade date
Nov 9, 2026
8:04 AM ET 8-K
Financial Results Cohen & Co Inc. COHN

Cohen & Co Financial Results

Cohen & Co Inc. reported third quarter 2026 financial results, generating $32.4 million in total revenue and $6.9 million in enterprise net income. The company's capital markets division underwrote six SPAC IPOs during the quarter, though results were impacted by $17 million in mark-to-market adjustments. Additionally, the board declared a quarterly dividend of $0.25 per share and appointed Daniel G. Cohen as CEO.

Term
3 years

“We are encouraged by the continued strong performance in our full-service boutique investment bank, Cohen & Company Capital Markets (“CCM”), and in our gestation repo business. During the third quarter, CCM underwrote six SPAC IPOs and one closed-end fund, raising $1.8 billion for clients, and advised on and raised capital for eight de-SPAC transactions, exemplifying its status as a leading SPAC advisor on Wall Street.”

Daniel G. Cohen, Executive Chairman and Chief Executive Officer

“While third quarter results were unfavorably impacted by more than $17 million of mark-to-market adjustments in our investment banking and new issue revenue line, in large part due to the environment in our businesses, we still generated $6.9 million of enterprise net income and $648,000 of adjusted pre-tax income.”

Daniel G. Cohen, Executive Chairman and Chief Executive Officer
8:03 AM ET 10-Q
Financial Results Accelerant Holdings ARX

Accelerant Holdings Q3 2026 Results: Net Loss of $9.2M, Loss Narrows

Accelerant Holdings reported a net income of $66.7 million for the nine months ended September 30, 2026, a significant recovery from a net loss of $1,346.1 million in the prior year period, which was heavily impacted by a $1.38 billion non-cash profits interest distribution expense. Total revenues grew to $908.8 million for the nine-month period, driven by increases in direct commission income and net earned premiums.

Key figure
Net loss $9.2M
8:03 AM ET 8-K
Investor Presentation Starling Oncology, Inc. STLN

Starling Oncology Investor Presentation

Starling Oncology, Inc. has prepared a formal investor presentation to be used in upcoming meetings with investors. The presentation, dated November 12, 2026, was furnished as an exhibit to the 8-K filing and includes a discussion of the company's strategy and financial trends.

8:03 AM ET 10-Q
Financial Results Patriot National Bancorp Inc PNBK

Patriot National Bancorp Q3 2026 Results: Turns Profitable, Net Income $1.2M

Patriot National Bancorp reported a net income of $1.2 million for the third quarter of 2026, a significant improvement from a $2.7 million loss in the prior year period. Total assets grew to $1.5 billion as of September 30, 2026, driven by a substantial increase in loans receivable and deposits, though the company recorded a comprehensive loss of $17.7 million for the first nine months of 2026 due to unrealized losses on investment securities.

Key figure
Net income $1.2M
8:02 AM ET Form 4
Insider Buying Hornbeck Offshore Services, Inc. HOS

Hornbeck Offshore Services President & CEO Todd M. Hornbeck Buys $1.5M of Stock

Todd M. Hornbeck, President & CEO, bought 280,866 shares of Hornbeck Offshore Services, Inc. at $5.28 to $5.48 a share (average $5.34) in 2 transactions, worth $1.5M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 5,950,514 (+1.6%).

Value
$1.5M
Shares
280,865
Average price
$5.34
Role
President & CEO
Holding change
+1.6%
Trade date
Nov 10, 2026 to Nov 11, 2026
8:02 AM ET 8-K
Financial Results Kyverna Therapeutics, Inc. KYTX

Kyverna Therapeutics Financial Results

Kyverna Therapeutics reported Q3 2026 financial results and announced the completion of its rolling BLA submission to the FDA for miv-cel in Stiff Person Syndrome (SPS). The company ended the quarter with $312.4 million in cash and equivalents, which it expects will fund operations into 2028 as it prepares for a potential commercial launch in 2027.

Term
Q3 2026

“Kyverna is very proud to submit the first BLA for a CAR T-cell therapy in autoimmune disease, paving the way for a potential new standard of care with a single dose, designed to reset the immune system and free patients from lifelong disease and chronic immunotherapies.”

Warner Biddle, Chief Executive Officer of Kyverna
8:02 AM ET 8-K
Research Collaboration Oncolytics Biotech Inc ONCY

Oncolytics Biotech Research Collaboration with Coherus Oncology, Inc.

Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology to evaluate pelareorep in combination with LOQTORZI (toripalimab-tpzi) for the treatment of squamous cell anal carcinoma (SCAC). The clinical study, expected to begin in Q1 2027, will target second-line patients who have progressed on standard-of-care treatments.

Counterparty
Coherus Oncology, Inc.
8:01 AM ET 8-K
Financial Results Btcs Inc. BTCS

Btcs Financial Results

BTCS Inc. reported record Q3 2026 financial results, highlighted by a 67% sequential revenue increase to $4.1 million and record gross profit of $3.5 million. The company surpassed its full-year gross profit target of $6 million in just nine months, driven primarily by the expansion of its Imperium liquidity pool positions to approximately $41 million.

Term
Q3 2026

“The third quarter was a breakout quarter for BTCS and Imperium. BTCS delivered a record $3.5 million in gross profit at an 86% gross margin, surpassing our full-year gross profit target of $6 million with a full quarter remaining in 2026. That performance was driven by Imperium, where we grew our paired liquidity pool positions from approximately $8 million to approximately $41 million and expanded into a multi-chain strategy with the integration of Base. Looking to the fourth quarter, we intend to keep scaling Imperium, and we expect it to remain the leading driver of our business.”

Charles Allen, Chief Executive Officer
8:01 AM ET 8-K
Financial Results Monopar Therapeutics MNPR

Monopar Therapeutics Financial Results

Monopar Therapeutics reported third quarter 2026 financial results, including a net loss of $6.2 million and a cash position of $129.4 million. The company highlighted progress on its rolling NDA submission for ALXN1840 in Wilson disease, which it expects to complete within the next several weeks.

8:01 AM ET 8-K
Financial Results Grace Therapeutics, Inc. GRCE

Grace Therapeutics Financial Results

Grace Therapeutics reported financial results for the quarter ended September 30, 2026, with a net loss of $2.1 million. The company is currently focused on resubmitting its New Drug Application (NDA) for GTx-104 after addressing CMC and non-clinical items identified by the FDA. Management noted that a recent $10 million financing has extended the company's cash runway through the end of 2028.

“With no clinical safety or efficacy deficiencies identified in the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL), we continue to execute our plan to address the chemistry, manufacturing and controls (CMC) and non-clinical data items, and are making progress toward resubmission of our New Drug Application (NDA) for GTx-104.”

Prashant Kohli, Chief Executive Officer

“The financing concluded in August extends our expected cash runway through the end of calendar 2028, and positions us well as we work toward NDA resubmission.”

Prashant Kohli, Chief Executive Officer
8:01 AM ET 8-K
M&A Deal Hancock Whitney Corp HWC

Hancock Whitney Signs $3.2B M&A Deal with Trustmark Corporation

Hancock Whitney Corporation (HWC) has entered into a definitive agreement to acquire Trustmark Corporation (TRMK) in an all-stock transaction valued at approximately $3.2 billion. The merger will create a premier Gulf South regional bank with approximately $58 billion in assets and is expected to close in late Q1 2027.

Value
$3.2B
Counterparty
Trustmark Corporation

“By bringing together two high-performing banks with shared values, complementary capabilities, and a relentless focus on client success, we create an organization that is stronger as one. This combination enhances our platform, expands growth opportunities, strengthens the core deposit franchise, and broadens the capabilities we deliver to consumer and business clients.”

John M. Hairston, President and CEO of Hancock Whitney

“Given the strong cultural alignment and complementary business lines between our two organizations, we believe this transaction will generate substantial value and meaningful benefits for our customers, shareholders, associates, and communities.”

Duane Dewey, President and CEO of Trustmark
8:01 AM ET 10-Q
Financial Results Monopar Therapeutics MNPR

Monopar Therapeutics Q3 2026 Results: Net Loss of $6.2M, Loss Widens

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on radiopharmaceuticals and copper-chelating therapies like ALXN1840. For the nine months ended September 30, 2026, the company reported 6,776,773 shares of common stock outstanding and continues to incur significant losses as it prepares a rolling NDA submission for ALXN1840.

Key figure
Net loss $6.2M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.